Serious adverse events · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Deaths · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Moderate benefit: at least 30% reduction in pain, or PGIC much or very much improved · Adults with chronic neuropathic pain
1 finding from 1 review
Intervention not reported
Substantial benefit: at least 50% reduction in pain, or PGIC much improved · Adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Lack of efficacy withdrawal in randomised double‐blind phase · Adults with chronic neuropathic pain
1 finding from 1 review
Intervention not reported
Adverse event withdrawal in randomised double‐blind phase · Adults with chronic neuropathic pain
1 finding from 1 review
Intervention not reported
Serious adverse events · Adults with chronic neuropathic pain
1 finding from 1 review
Intervention not reported
Deaths · Adults with chronic neuropathic pain
1 finding from 1 review
At least 50% reduction in pain · adults with fibromyalgia
1 finding from 1 review
Adverse events as N of participants with at least one adverse event objective · adults with fibromyalgia enrolled in EERW studies
1 finding from 1 review
Serious adverse events · adults with fibromyalgia enrolled in EERW studies
1 finding from 1 review
Death · adults with fibromyalgia enrolled in EERW studies
1 finding from 1 review
PGIC very much improved · adults with fibromyalgia
1 finding from 1 review
At least 30% reduction in pain · adults with fibromyalgia
1 finding from 1 review
Moderate benefit · adults with fibromyalgia
1 finding from 1 review
Lack of efficacy withdrawal · adults with fibromyalgia
1 finding from 1 review
Withdrawals due to adverse events · adults with fibromyalgia
1 finding from 1 review
Serious adverse events · adults with fibromyalgia
1 finding from 1 review
Death · adults with fibromyalgia
1 finding from 1 review
Maintenance of initial therapeutic response of at least 30% pain intensity reduction over baseline and continued treatment at 13 or 26 weeks (equivalent to 'moderate benefit') · adults with fibromyalgia enrolled in EERW studies
1 finding from 1 review